Actinium Pharmaceuticals (ATNM) Stock Forecast, Price & News

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions

Is Actinium Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Actinium Pharmaceuticals stock.
View analyst ratings for Actinium Pharmaceuticals or view top-rated stocks.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 927,200 shares, a decline of 30.8% from the April 15th total of 1,340,000 shares. Based on an average daily volume of 818,000 shares, the short-interest ratio is presently 1.1 days.
View Actinium Pharmaceuticals' Short Interest.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) released its quarterly earnings data on Tuesday, March, 30th. The biotechnology company reported ($0.37) EPS for the quarter, meeting analysts' consensus estimates of ($0.37). Actinium Pharmaceuticals had a negative net margin of 2,165.56% and a negative trailing twelve-month return on equity of 32.48%.
View Actinium Pharmaceuticals' earnings history.

When did Actinium Pharmaceuticals' stock split? How did Actinium Pharmaceuticals' stock split work?

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of Actinium Pharmaceuticals stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for ATNM?

3 brokerages have issued 1 year target prices for Actinium Pharmaceuticals' shares. Their forecasts range from $25.00 to $45.00. On average, they anticipate Actinium Pharmaceuticals' stock price to reach $31.67 in the next twelve months. This suggests a possible upside of 468.5% from the stock's current price.
View analysts' price targets for Actinium Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the following people:

• Mr. Sandesh C. Seth M.B.A., M.S., MBA, Chairman & CEO (Age 58, Pay $1.04M)
• Mr. Steven O'Loughlin BS, CFO & Corp. Sec. (Age 36, Pay $520k)
• Dr. Paul Diamond Esq., Ph.D., VP of Patent & Legal Counsel
• Dr. David Gould, Sr. VP of Corp. Devel. & Corp. Affairs
• Dr. Bernie Cunningham, Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
• Dr. Qing Liang, VP & Head of Radiation Sciences
• Dr. Robert N. Daly M.S., Ph.D., VP & Head of Clinical Operations
• Dr. Mamata Gokhale, VP & Global Head of Regulatory Affairs
• Dr. Avinash Desai M.D., Chief Medical Officer
• Dr. Arun Swaminathan Ph.D., Chief Bus. & Commercial Officer

Who are some of Actinium Pharmaceuticals' key competitors?

Some companies that are related to Actinium Pharmaceuticals include Collegium Pharmaceutical (COLL), Amarin (AMRN), Rani Therapeutics (RANI), Imago BioSciences (IMGO), Tricida (TCDA), Basilea Pharmaceutica (BPMUF), ANI Pharmaceuticals (ANIP), Amylyx Pharmaceuticals (AMLX), Amryt Pharma (AMYT), Intercept Pharmaceuticals (ICPT), Bicycle Therapeutics (BCYC), Foghorn Therapeutics (FHTX), Tango Therapeutics (TNGX), Calliditas Therapeutics AB (publ) (CALT) and Stoke Therapeutics (STOK).
View all of ATNM's competitors.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.88%), BlackRock Inc. (1.04%), Blair William & Co. IL (0.45%), State Street Corp (0.28%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%).
View institutional ownership trends for Actinium Pharmaceuticals.

Which institutional investors are selling Actinium Pharmaceuticals stock?

ATNM stock was sold by a variety of institutional investors in the last quarter, including ACT Capital Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Actinium Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Actinium Pharmaceuticals stock?

ATNM stock was bought by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Simplex Trading LLC, Group One Trading L.P., State Street Corp, Cutler Group LP, and BlackRock Inc..
View insider buying and selling activity for Actinium Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $5.57.

How much money does Actinium Pharmaceuticals make?

Actinium Pharmaceuticals has a market capitalization of $132.48 million and generates $1.14 million in revenue each year.

How many employees does Actinium Pharmaceuticals have?

Actinium Pharmaceuticals employs 32 workers across the globe.

What is Actinium Pharmaceuticals' official website?

The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at (646) 677-3870 or via email at [email protected].